Dunlop Sinclair A.'s most recent trade in Apellis Pharmaceuticals Inc was a trade of 11,199 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 11,199 | 11,199 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 6,267 | 158,393 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Sep 2024 | 4,600 | 0 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.19 per share. | 23 Sep 2024 | 4,600 | 152,126 (0%) | 0% | 13.2 | 60,674 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 36.09 per share. | 16 Sep 2024 | 29,476 | 107,524 (0%) | 0% | 36.1 | 1,063,789 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 36.79 per share. | 16 Sep 2024 | 7,524 | 100,000 (0%) | 0% | 36.8 | 276,808 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.19 per share. | 28 Jun 2024 | 900 | 134,418 (0%) | 0% | 13.2 | 11,871 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2024 | 900 | 4,600 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 39.22 per share. | 21 Jun 2024 | 35,305 | 138,693 (0%) | 0% | 39.2 | 1,384,662 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 39.63 per share. | 21 Jun 2024 | 1,695 | 136,998 (0%) | 0% | 39.6 | 67,173 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.19 per share. | 12 Apr 2024 | 1,500 | 133,518 (0%) | 0% | 13.2 | 19,785 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Apr 2024 | 1,500 | 5,500 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 57.18 per share. | 19 Mar 2024 | 18,681 | 173,998 (0%) | 0% | 57.2 | 1,068,161 | Common Stock |
| Apellis Pharmaceuticals Inc | Dunlop Sinclair A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 5,748 | 5,748 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 3,341 | 132,018 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Dunlop Sinclair A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 6,274 | 7,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | A. Dunlop Sinclair | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.19 per share. | 14 Dec 2023 | 6,274 | 128,677 (0%) | 0% | 13.2 | 82,754 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 61.14 per share. | 01 Dec 2023 | 24,000 | 192,679 (0%) | 0% | 61.1 | 1,467,240 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 74.05 per share. | 03 Apr 2023 | 500 | 131,297 (0%) | 0% | 74.1 | 37,025 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 65.33 per share. | 01 Mar 2023 | 500 | 131,797 (0%) | 0% | 65.3 | 32,665 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 52.61 per share. | 01 Feb 2023 | 500 | 132,297 (0%) | 0% | 52.6 | 26,305 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 50.70 per share. | 03 Jan 2023 | 500 | 132,797 (0%) | 0% | 50.7 | 25,350 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 7,441 | 7,441 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 3,867 | 133,297 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 49.93 per share. | 01 Dec 2022 | 500 | 129,430 (0%) | 0% | 49.9 | 24,965 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 60.83 per share. | 01 Nov 2022 | 500 | 129,930 (0%) | 0% | 60.8 | 30,415 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 65.00 per share. | 08 Sep 2022 | 15,000 | 240,679 (0%) | 0% | 65 | 975,000 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2022 | 4,306 | 13,274 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.19 per share. | 25 Aug 2022 | 4,306 | 130,430 (0%) | 0% | 13.2 | 56,796 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 16 Aug 2022 | 25,394 | 126,124 (0%) | 0% | 14 | 355,516 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2022 | 25,394 | 0 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 65.63 per share. | 11 Aug 2022 | 30,000 | 255,679 (0%) | 0% | 65.6 | 1,968,900 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jul 2022 | 9,606 | 25,394 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 21 Jul 2022 | 9,606 | 100,730 (0%) | 0% | 14 | 134,484 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 46.79 per share. | 27 Jun 2022 | 1,341 | 1,341 (0%) | 0% | 46.8 | 62,743 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 23 Jun 2022 | 15,000 | 285,679 (0%) | 0% | 45 | 675,000 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 22 Apr 2022 | 20,000 | 91,124 (0%) | 0% | 14 | 280,000 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Apr 2022 | 20,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 8,554 | 8,554 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 4,230 | 71,124 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 10 Sep 2021 | 6,894 | 66,894 (0%) | 0% | 14 | 96,516 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2021 | 6,894 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Other type of transaction at price $ 0.00 per share. | 01 Jun 2021 | 31,855 | 0 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Other type of transaction at price $ 0.00 per share. | 01 Jun 2021 | 13,108 | 73,108 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Other type of transaction at price $ 0.00 per share. | 01 Jun 2021 | 2,682 | 303,361 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 51.66 per share. | 18 May 2021 | 64,179 | 110,549 (0%) | 0% | 51.7 | 3,315,487 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 53.78 per share. | 18 May 2021 | 36,387 | 59,946 (0%) | 0% | 53.8 | 1,956,893 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 54.57 per share. | 18 May 2021 | 22,318 | 37,628 (0%) | 0% | 54.6 | 1,217,893 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 52.63 per share. | 18 May 2021 | 14,216 | 96,333 (0%) | 0% | 52.6 | 748,188 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 53.50 per share. | 18 May 2021 | 10,388 | 309,091 (0%) | 0% | 53.5 | 555,758 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 18 May 2021 | 7,612 | 300,679 (0%) | 0% | 50 | 380,600 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 48.10 per share. | 18 May 2021 | 5,773 | 31,855 (0%) | 0% | 48.1 | 277,681 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 52.01 per share. | 18 May 2021 | 1,200 | 319,479 (0%) | 0% | 52.0 | 62,412 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 54.02 per share. | 18 May 2021 | 800 | 308,291 (0%) | 0% | 54.0 | 43,216 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 23 Apr 2021 | 10,000 | 60,000 (0%) | 0% | 14 | 140,000 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Apr 2021 | 10,000 | 61,894 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 16 Apr 2021 | 50,000 | 50,000 (0%) | 0% | 14 | 700,000 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2021 | 50,000 | 71,894 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2021 | 27,600 | 27,600 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 55.01 per share. | 14 Dec 2020 | 17,132 | 174,942 (0%) | 0% | 55.0 | 942,431 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 53.86 per share. | 14 Dec 2020 | 7,654 | 192,074 (0%) | 0% | 53.9 | 412,244 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 56.25 per share. | 14 Dec 2020 | 214 | 174,728 (0%) | 0% | 56.3 | 12,038 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 51.00 per share. | 04 Dec 2020 | 9,470 | 199,728 (0%) | 0% | 51 | 482,970 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 50.41 per share. | 04 Dec 2020 | 9,094 | 209,198 (0%) | 0% | 50.4 | 458,429 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 50.04 per share. | 04 Dec 2020 | 5,052 | 219,676 (0%) | 0% | 50.0 | 252,802 | Common Stock |
| Apellis Pharmaceuticals Inc | A. Sinclair Dunlop | Director | Sale of securities on an exchange or to another person at price $ 51.05 per share. | 04 Dec 2020 | 1,384 | 218,292 (0%) | 0% | 51.0 | 70,653 | Common Stock |